ClinicalTrials.gg
Active, not recruitingNCT06691984Updated May 15, 2026

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

A Phase 3 interventional study of Xaluritamig and Abiraterone in Metastatic Castration-resistant Prostate Cancer, sponsored by Amgen. Active, not recruiting at 164 sites in 22 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Primary conditionProstatic NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prostatic Neoplasms
Why
  1. The study's listed conditions name Prostatic Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
707
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Prostatic Neoplasms by Amgen — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Amgen.

Enrollment
5th of 21
707 · median 64
Started
2024
with 2 others
Phase 3
9 of 23
1 open now
Registered
20th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 5th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 in phase 3, and was the 20th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 23 studies in Prostatic Neoplasms by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Amgen, or all of them as a file.
02

Study summary

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Oncology
  • Xaluritamig
  • Cabazitaxel
  • Prostate cancer
  • Abiraterone
  • Enzalutamide
04

In context

Prostatic Neoplasms Reclassified

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

This study's enrollment of 707 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participant has provided prior to initiation of any study-specific activities/procedures.
  • Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
  • Participant must have histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate. Mixed histologies (eg, adenocarcinoma with neuroendocrine component) are not permitted.
  • mCRPC with ≥ 1 lesion that is present on baseline computed tomography (CT), magnetic resonance imaging (MRI), or bone scan imaging obtained within 28 days prior to enrollment.
  • Evidence of progressive disease, defined as 1 or more PCWG3 criteria:

    • Serum PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start value is 2.0 ng/mL.
    • Soft-tissue progression defined as an increase ≥ 20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-target lesions.
    • Progression of bone disease: defined by the appearance of at least 2 new bone lesion(s) by bone scan (as per the 2+2 PCWG3 criteria).
  • Participants must have had a prior orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone (\< 50 ng/dL or \< 1.7 nmol/L).
  • Prior progression on at least one ARDT (enzalutamide, abiraterone, apalutamide, darolutamide).
  • Prior treatment with only one taxane therapy in the mCRPC setting. Note: Prior treatment with docetaxel in the metastatic hormone-sensitive prostate cancer (mHSPC) setting is permitted; however, participants must have also received one, and only one, taxane therapy in the mCRPC setting.
  • performance status (ECOG PS) of 0 or 1.
  • Adequate organ function.
  • of ≥ 12 weeks per the treating physician's assessment.

Key Exclusion Criteria:

Prior \& Concomitant Therapy:

  • Prior six transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeted therapy.
  • Any anticancer therapy, immunotherapy, or agent within 4 weeks prior to the first dose of study treatment, not including androgen receptor pathway inhibitors (ARPIs) (abiraterone, enzalutamide, darolutamide, apalutamide): minimum of 2 weeks prior to the first dose of study treatment and androgen suppression therapy (eg, luteinizing hormone-releasing hormone/gonadotropin-releasing hormone [LHRH/GnRH] analogue [agonist/antagonist]).
  • Prior Prostate-Specific Membrane Antigen (PSMA) radioligand therapy (RLT) within 3 months of the first dose of study treatment unless participants received \< 2 cycles of therapy.
  • Prior palliative radiotherapy within 2 weeks of first dose of study treatment. Participants must have recovered from all radiation-related toxicities.
  • Concurrent cytotoxic chemotherapy, ARDT, immunotherapy, radioligand therapy, PARP inhibitor, biological therapy, investigational therapy. Note: Prior treatment with a PARP inhibitor is permitted as long as not within 4 weeks before first dose of study treatment.
  • Prior radionuclide therapy (Radium-223) within 2 months of first dose of study treatment.
  • Treatment with live and within 4 weeks before the first dose of study treatment.

Disease Related:

  • Participants with a history of central nervous system (CNS) metastasis. Note: Participants with treated, asymptomatic, and clinically stable dural metastases are eligible.
  • Unresolved toxicities from prior anti-tumor therapy not having resolved to version 5.0 events grade above 1 or baseline, with the exception of alopecia or toxicities that are stable and well controlled AND there is an agreement to allow inclusion by both the investigator and the sponsor.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
707 participants (actual)

Study arms

  • Experimental
    Xaluritamig

    Participants with metastatic castration-resistant prostate cancer (mCRPC) will be randomized to receive Xaluritamig as an intravenous (IV) infusion.

    Drug: Xaluritamig

  • Active comparator
    Cabazitaxel/Abiraterone/Enzalutamide

    Participants with mCRPC will be randomized to receive cabazitaxel as an IV infusion, or a second androgen receptor-directed therapy of either abiraterone as oral tablets, or enzalutamide as oral tablets at the investigator's discretion.

    Drug: Abiraterone · Drug: Enzalutamide · Drug: Cabazitaxel

Interventions

07

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 53 months

Secondary outcomes

  1. Radiographic Progression-free Survival (rPFS) per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR)

    Time frame: Up to approximately 53 months

  2. Objective Response Rate per Modified RECIST v1.1 as Assessed by BICR

    Time frame: Up to approximately 53 months

  3. Duration of Response (DOR) per Modified RECIST v1.1 as Assessed by BICR

    Time frame: Up to approximately 53 months

  4. Disease Control Rate per Modified RECIST v1.1 as Assessed by BICR

    Time frame: Up to approximately 53 months

  5. Time to Response (TTR) per Modified RECIST v1.1 as Assessed by BICR

    Time frame: Up to approximately 53 months

  6. Time to First Symptomatic Skeletal Events (SSE)

    Time frame: Up to approximately 53 months

  7. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 53 months

  8. Change from Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain Score

    Time frame: Baseline and approximately 53 months

  9. Change from Baseline in BPI-SF Pain Intensity Scale Score

    Time frame: Baseline and approximately 53 months

  10. Change from Baseline in BPI-SF Pain Interference Scale Score

    Time frame: Baseline and approximately 53 months

  11. Change from baseline in the European Quality of Life 5 Domain 5 Level Scale (EQ-5D-5L) Utility Score

    Time frame: Baseline and approximately 53 months

  12. Change from baseline in the EQ-5D-5L Visual Analogue Scale (VAS)

    Time frame: Baseline and approximately 53 months

  13. Change from Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score and Subscale Score

    Time frame: Baseline and approximately 53 months

  14. Time to Worsening in BPI-SF Worst Pain Score

    Time frame: Up to approximately 53 months

  15. Time to Worsening in BPI-SF Pain Intensity Scale Score

    Time frame: Up to approximately 53 months

  16. Time to Worsening in BPI-SF Pain Interference Scale Score

    Time frame: Up to approximately 53 months

  17. Time to Worsening in FACT-P Total Score

    Time frame: Up to approximately 53 months

  18. Time to Pain Improvement in Participants with Moderate/Severe Pain at Baseline

    Time frame: Up to approximately 53 months

  19. Time to Pain Improvement after Worsening in BPI-SF Pain Intensity Scale Score

    Time frame: Up to approximately 53 months

  20. Time to Pain Improvement after Worsening in BPI-SF Pain Interference Scale

    Time frame: Up to approximately 53 months

  21. Number of Patient-Reported Symptomatic AEs per Patient-reported Outcome - Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library

    Time frame: Up to approximately 53 months

  22. Patient-Reported Summary Scores for Overall Bother of Side Effects per FACT-P

    Time frame: Up to approximately 53 months

  23. Percentage of Participants Achieving a ≥50% Reduction in Prostate-specific Antigen (PSA) (PSA50)

    Time frame: Up to approximately 53 months

  24. Percentage of Participants Achieving a ≥90% Reduction in PSA (PSA90)

    Time frame: Up to approximately 53 months

  25. Maximum Serum Concentration (Cmax) of Xaluritamig

    Time frame: Up to approximately 53 months

  26. Time to Cmax (Tmax) of Xaluritamig

    Time frame: Up to approximately 53 months

  27. Minimum Serum Concentration (Cmin) of Xaluritamig

    Time frame: Up to approximately 53 months

  28. Area Under the Concentration-time Curve (AUC) of Xaluritamig

    Time frame: Up to approximately 53 months

  29. Accumulation Following Multiple Dosing of Xaluritamig

    Time frame: Up to approximately 53 months

  30. Half-life (t1/2) of Xaluritamig

    Time frame: Up to approximately 53 months

  31. Number of Participants with Anti-xaluritamig Antibody

    Time frame: Up to approximately 53 months

08

Study locations

164 sites

Showing the first 100 of 164 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 48 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 18, 2024
StartActual
Dec 9, 2024
Primary completionEst.
Jan 2, 2029
CompletionEst.
Jul 30, 2029
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06691984
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
Dec 9, 2024
Primary completion
Jan 2, 2029 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
May 15, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xaluritamig

Start the discussion